Disseminated Intravascular Coagulopathy Is Associated with the Outcome of Persistent Inflammation, Immunosuppression and Catabolism Syndrome
Abstract
:1. Introduction
2. Materials and Methods
2.1. Dataset and Cohort
2.2. Classification of PIICS, Non-PIICS, Early Recovery and Early Death
2.3. Other Outcome Evaluation
2.4. Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Conflicts of Interest
References
- Gentile, L.F.; Cuenca, A.G.; Efron, P.A.; Ang, D.; McKinley, B.A.; Moldawer, L.L.; Moore, F.A. Persistent inflammation and immunosuppression: A common syndrome and new horizon for surgical intensive care. J. Trauma Acute Care Surg. 2012, 72, 1491–1501. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mira, J.C.; Gentile, L.F.; Mathias, B.J.; Efron, P.A.; Brakenridge, S.C.; Mohr, A.M.; Moore, F.A.; Moldawer, L.L. Sepsis pathophysiology, chronic critical illness, and persistent inflammation-immunosuppression and catabolism syndrome. Crit. Care Med. 2017, 45, 253–262. [Google Scholar] [CrossRef] [PubMed]
- Hawkins, R.B.; Raymond, S.L.; Stortz, J.A.; Horiguchi, H.; Brakenridge, S.C.; Gardner, A.; Efron, P.A.; Bihorac, A.; Segal, M.; Moore, F.A.; et al. Chronic critical illness and the persistent inflammation, immunosuppression, and catabolism syndrome. Front. Immunol. 2018, 9, 1511. [Google Scholar] [CrossRef] [PubMed]
- Kahn, J.M.; Le, T.; Angus, D.C.; Cox, C.E.; Hough, C.L.; White, D.B.; Yende, S.; Carson, S.S.; ProVent Study Group Investigators. The epidemiology of chronic critical illness in the United States. Crit. Care Med. 2015, 43, 282–287. [Google Scholar] [CrossRef]
- Stortz, J.A.; Mira, J.C.; Raymond, S.L.; Loftus, T.J.; Ozrazgat-Baslanti, T.; Wang, Z.; Ghita, G.L.; Leeuwenburgh, C.; Segal, M.S.; Bihorac, A.; et al. Benchmarking clinical outcomes and the immunocatabolic phenotype of chronic critical illness after sepsis in surgical intensive care unit patients. J. Trauma Acute Care Surg. 2018, 84, 342–349. [Google Scholar] [CrossRef]
- Nakamura, K.; Ogura, K.; Nakano, H.; Naraba, H.; Takahashi, Y.; Sonoo, T.; Hashimoto, H.; Morimura, N. C-reactive protein clustering to clarify persistent inflammation, immunosuppression and catabolism syndrome. Intensive Care Med. 2020, 46, 437–443. [Google Scholar] [CrossRef]
- Gando, S.; Levi, M.; Toh, C.H. Disseminated intravascular coagulation. Nat. Rev. Dis. Primers 2016, 2, 16037. [Google Scholar] [CrossRef]
- Foley, J.H.; Conway, E.M. Cross talk pathways between coagulation and inflammation. Circ. Res. 2016, 118, 1392–1408. [Google Scholar] [CrossRef]
- Horiguchi, H.; Loftus, T.J.; Hawkins, R.B.; Raymond, S.L.; Stortz, J.A.; Hollen, M.K.; Weiss, B.P.; Miller, E.S.; Bihorac, A.; Larson, S.D.; et al. Innate immunity in the persistent inflammation, immunosuppression, and catabolism syndrome and its implications for therapy. Front. Immunol. 2018, 9, 595. [Google Scholar] [CrossRef]
- Gando, S.; Saitoh, D.; Ogura, H.; Mayumi, T.; Koseki, K.; Ikeda, T.; Ishikura, H.; Iba, T.; Ueyama, M.; Eguchi, Y.; et al. Natural history of disseminated intravascular coagulation diagnosed based on the newly established diagnostic criteria for critically ill patients: Results of a multicenter, prospective survey. Crit. Care Med. 2008, 36, 145–150. [Google Scholar] [CrossRef] [Green Version]
- Zhang, Z. Structural equation modeling in the context of clinical research. Ann. Transl. Med. 2017, 5, 102. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hurley, J.C. Structural equation modeling the “control of gut overgrowth” in the prevention of ICU-acquired Gram-negative infection. Crit. Care 2020, 24, 189. [Google Scholar] [CrossRef]
- Rosenthal, M.D.; Moore, F.A. Persistent inflammatory, immunosuppressed, catabolic syndrome (PICS): A new phenotype of multiple organ failure. J. Adv. Nutr. Hum. Metab. 2015, 1, e784. [Google Scholar] [PubMed] [Green Version]
- Rosenthal, M.D.; Moore, F.A. Persistent inflammation, immunosuppression, and catabolism: Evolution of multiple organ dysfunction. Surg. Infect. (Larchmt) 2016, 17, 167–172. [Google Scholar] [CrossRef] [PubMed]
- Moore, F.A.; Phillips, S.M.; McClain, C.J.; Patel, J.J.; Martindale, R.G. nutrition support for persistent inflammation, immunosuppression, and catabolism syndrome. Nutr. Clin. Pract. 2017, 32 (Suppl. 1), 121S–127S. [Google Scholar] [CrossRef] [Green Version]
- Kudo, D.; Sanui, M.; Takahashi, H.; Yoshikawa, Y.; Toshimitsu, H.; Satoshi, F.; for the Japan Septic Disseminated Intravascular Coagulation (J-Septic DIC) study group. Benefit profile of anticoagulant therapy in sepsis: A nationwide multicentre registry in Japan. Crit. Care 2016, 20, 229. [Google Scholar]
- Ogura, H.; Gando, S.; Saitoh, D.; Takeyama, N.; Kushimoto, S.; Fujishima, S.; Mayumi, T.; Araki, T.; Ikeda, H.; Kotani, J.; et al. Epidemiology of severe sepsis in Japanese intensive care units: A prospective multicenter study. J. Infect. Chemother. 2014, 20, 157–162. [Google Scholar] [CrossRef]
- Yamakawa, K.; Murao, S.; Aihara, M. Recombinant human soluble thrombomodulin in sepsis-induced coagulopathy: An updated systematic review and meta-analysis. Thromb. Haemost. 2019, 119, 56–65. [Google Scholar] [CrossRef]
- Efron, P.A.; Mohr, A.M.; Bihorac, A.; Horiguchi, H.; Hollen, K.K.; Segal, M.S.; Baker, H.V.; Leeuwenburgh, C.; Moldawer, L.L.; Moore, A.F.; et al. Persistent inflammation, immunosuppression, and catabolism and the development of chronic critical illness after surgery. Surgery 2018, 164, 178–184. [Google Scholar] [CrossRef]
- Flick, M.J.; Du, X.; Witte, D.P.; Jiroušková, M.; Soloviev, D.A.; Busuttil, S.J.; Plow, E.F.; Degen, J.L. Leukocyte engagement of fibrin(ogen) via the integrin receptor alphaMbeta2/Mac-1 is critical for host inflammatory response in vivo. J. Clin. Investig. 2004, 113, 1596–1606. [Google Scholar] [CrossRef] [Green Version]
- Winer, L.K.; Beckmann, N.; Veile, R.A.; Goodman, M.D.; Caldwell, C.C.; Nomellini, V. Consumptive coagulopathy is associated with organ dysfunction during PICS. Am. J. Physiol. Lung. Cell Mol. Physiol. 2019, 316, L946–L952. [Google Scholar] [CrossRef] [PubMed]
- Levi, M.; van der Poll, T. Coagulation and sepsis. Thromb. Res. 2017, 149, 38–44. [Google Scholar] [CrossRef] [PubMed]
- Frydrych, L.M.; Fattahi, F.; He, K.; Ward, P.A.; Delano, M.J. Diabetes and sepsis: Risk, recurrence, and ruination. Front. Endocrinol. 2017, 8, 271. [Google Scholar] [CrossRef] [Green Version]
- Loftus, T.J.; Mira, J.C.; Stortz, J.A.; Ozrazgat-Baslanti, T.; Ghita, G.L.; Wang, Z.; Brumback, B.A.; Ungaro, R.F.; Bihorac, A.; Leeuwenburgh, C.; et al. Persistent inflammation and anemia among critically ill septic patients. J. Trauma Acute Care Surg. 2019, 86, 260–267. [Google Scholar] [CrossRef] [PubMed]
Definition of PIICS | |
---|---|
Persistent | Prolonged hospitalization > 14 days |
Inflammation | C-reactive protein > 3.0 mg/dL |
Immunosuppression | Total lymphocyte count < 800/mm3 |
Catabolism | Weight loss of >10% or body mass index < 18 during hospitalization |
Creatinine height index < 80% | |
Albumin < 3.0 gm/dL | |
Pre-albumin < 10 mg/dL | |
Retinol binding protein < 10 μg/dL |
ISTH Overt DIC | Non-ISTH Overt DIC | ||
---|---|---|---|
N | 826 | 4571 | p-Value |
Age | 73.5 ± 16.5 | 70.2 ± 18.5 | <0.0001 * |
Male, n (%) | 499 (60.4) | 2619 (57.3) | 0.092 |
ICU on admission, n (%) | 312 (37.7) | 803 (17.6) | <0.0001 * |
SOFA | 7 (4, 10) | 4 (2, 7) | <0.0001 * |
APACHE II | 18 (13, 25) | 14 (10, 20) | <0.0001 * |
Adjunctive therapy on admission | |||
Mechanical ventilation, n (%) | 275 (33.3) | 525 (11.5) | <0.0001 * |
Duration (days) | 4 (2, 10) | 5 (2, 9) | 0.36 |
Renal replacement therapy, n (%) | 90 (10.9) | 242 (5.3) | <0.0001 * |
Duration (days) | 4 (2, 9.5) | 5 (2, 9) | 0.32 |
Extracorporeal membrane oxygenation | 11 (1.3) | 22 (0.5) | <0.0040 * |
duration (days) | 4 (1, 5) | 6 (3.75, 14) | 0.019 * |
Sepsis, n (%) | 231 (28.0) | 982 (21.5) | <0.0001 * |
Post-surgery, n (%) | 27 (3.3) | 183 (4.0) | 0.31 |
Laboratory findings on admission | |||
C-reactive protein, mg/dL | 1.98 (0.2, 9.7) | 0.8 (0.1, 5.4) | <0.0001 * |
Albumin, g/dL | 3.0 ± 0.9 | 3.4 ± 0.9 | <0.0001 * |
Lymphocyte counts, /μL | 1093 (586, 2340) | 1230 (720, 1890) | 0.59 |
ISTH overt DIC | Non-ISTH overt DIC | ||
---|---|---|---|
N | 826 | 4571 | p-Value |
Mortality, n (%) | 208 (25.2) | 312 (6.8) | <0.0001 * |
Length of hospital stay, days | 5 (2, 11) | 3 (2, 8) | <0.0001 * |
Barthel index at discharge | 60 (10, 100) | 85 (30, 100) | <0.0001 * |
Laboratory findings on day 14 | |||
C-reactive protein (mg/dL) | 3.6 (1.4, 7.2) | 2.1 (0.6, 5.5) | <0.0001 * |
Albumin (g/dL) | 2.3 ± 0.8 | 2.5 ± 0.8 | 0.0015* |
Lymphocyte (/μL) | 900 (520, 1308) | 1030 (665, 1405) | 0.075 |
Outcomes, n (%) | <0.0001 * | ||
PIICS | 121 (14.7) | 367 (8.0) | |
Prolonged hospital stay without PIICS | 41 (5.0) | 204 (4.5) | |
Early recovery | 490 (59.3) | 3758 (82.2) | |
Early death | 174 (21.1) | 242 (5.3) |
PIICS | Non-PIICS (Prolonged Hospital Stay without PIICS/Early Recovery) | Early Death | ||
---|---|---|---|---|
n | 488 | 4493 | 416 | p-Value |
ISTH overt DIC (%) | 121 (24.8) a,b | 531 (11.8) c | 174 (41.8) | <0.0001 * |
JAAM DIC (%) | 154 (31.6) a,b | 618 (13.8) c | 218 (52.4) | <0.0001 * |
Platelet (×10,000/μL) | 18.5 (12.4, 25.0) d,e | 19.4 (14.9, 24.4) f | 16.4 (10.4, 22.3) | <0.0001 * |
FDP (μg/dL) | 11.4 (5.7, 32.5) d,e | 4.9 (2.5, 13.7) f | 20.7 (6.4, 87.3) | <0.0001 * |
Dimer (μg/dL) | 7.6 (3.9, 19.1) d,e | 3.8 (1.3, 9.5) f | 12.9 (4.7, 50.8) | <0.0001 * |
PT (%) | 82.0 ± 25.9 g,h | 92.0 ± 24.1 i | 77.3 ± 29.6 | <0.0001 * |
APTT (s) | 32.9 ± 15.3 g,h | 30.6 ± 11.5 i | 41.2 ± 27.3 | <0.0001 * |
Fibrinogen (mg/dL) | 602.6 ± 267.2 g,h | 488.8 ± 217.2 i | 449.2 ± 219.3 | <0.0001 * |
Antithrombin activity (%) | 79.7 ± 24.4 g,h | 90.1 ± 26.1 i | 73.7 ± 25.2 | <0.0001 * |
Univariate Logistic Regression Analysis | Multivariate Logistic Regression Analysis | |||
---|---|---|---|---|
PIICS | Odds Ratio (95% CI) | p-Value | Odds Ratio (95% CI) | p-Value |
Age | 1.02 (1.01–1.03) | <0.0001 * | 1.02 (1.01–1.04) | 0.0038 * |
Male | 1.43 (1.17–1.74) | 0.0004 * | 2.10 (1.37–3.22) | 0.0006 * |
SOFA | 1.23 (1.19–1.28) | <0.0001 * | ||
APACHEII | 1.03 (1.02–1.04) | <0.0001 * | 1.04 (1.01–1.06) | 0.0012 * |
Sepsis | 3.70 (3.05–4.49) | <0.0001 * | 1.60 (1.00–2.55) | 0.049 * |
C-reactive protein (mg/dL) | 1.07 (1.06–1.08) | <0.0001 * | 1.02 (0.99–1.04) | 0.18 |
Albumin (g/dl) | 0.57 (0.52–0.62) | <0.0001 * | 0.60 (0.42–0.85) | 0.0037 * |
Lymphocyte counts (×1000/μL) # | 0.93 (0.83–1.03) | 0.15 | 1.19 (1.04–1.36) | 0.011 * |
Hemoglobin (g/dL) | 0.95 (0.93–0.98) | 0.0015 * | 1.09 (1.00–1.19) | 0.040 * |
Creatinine (mg/dL) | 1.11 (1.07–1.15) | <0.0001 * | 1.11 (1.01–1.21) | 0.034 * |
HbA1c (%) | 1.07 (0.99–1.14) | 0.071 | 1.14 (1.01–1.31) | 0.028 * |
ISTH overt DIC | 2.46 (1.96–3.08) | <0.0001 * | 1.58 (1.02–2.46) | 0.042 * |
JAAM DIC | 2.89 (2.35–3.56) | <0.0001 * | ||
Antithrombin activity (%) | 0.98 (0.98–0.99) | <0.0001 * | 0.99 (0.99–1.01) | 0.81 |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Nakamura, K.; Ogura, K.; Nakano, H.; Naraba, H.; Takahashi, Y.; Sonoo, T.; Hashimoto, H.; Goto, T. Disseminated Intravascular Coagulopathy Is Associated with the Outcome of Persistent Inflammation, Immunosuppression and Catabolism Syndrome. J. Clin. Med. 2020, 9, 2662. https://doi.org/10.3390/jcm9082662
Nakamura K, Ogura K, Nakano H, Naraba H, Takahashi Y, Sonoo T, Hashimoto H, Goto T. Disseminated Intravascular Coagulopathy Is Associated with the Outcome of Persistent Inflammation, Immunosuppression and Catabolism Syndrome. Journal of Clinical Medicine. 2020; 9(8):2662. https://doi.org/10.3390/jcm9082662
Chicago/Turabian StyleNakamura, Kensuke, Kentaro Ogura, Hidehiko Nakano, Hiromu Naraba, Yuji Takahashi, Tomohiro Sonoo, Hideki Hashimoto, and Tadahiro Goto. 2020. "Disseminated Intravascular Coagulopathy Is Associated with the Outcome of Persistent Inflammation, Immunosuppression and Catabolism Syndrome" Journal of Clinical Medicine 9, no. 8: 2662. https://doi.org/10.3390/jcm9082662
APA StyleNakamura, K., Ogura, K., Nakano, H., Naraba, H., Takahashi, Y., Sonoo, T., Hashimoto, H., & Goto, T. (2020). Disseminated Intravascular Coagulopathy Is Associated with the Outcome of Persistent Inflammation, Immunosuppression and Catabolism Syndrome. Journal of Clinical Medicine, 9(8), 2662. https://doi.org/10.3390/jcm9082662